Search Results
Venetoclax plus obinutuzumab improves PFS and MRD-negativity in patients with previously untreat...
CLL14: venetoclax-obinutuzumab improves PFS and MRD in untreated, reduced fitness CLL
Dr. Al-Sawaf on Updated PFS Data With Venetoclax Plus Obinutuzumab in CLL
Acalabrutinib, venetoclax and obinutuzumab in previously untreated patients with CLL
Obinutuzumab plus ibrutinib and venetoclax treatment continues to yield high response rates in CLL
Venetoclax and obinutuzumab combination therapy for CLL
Comment on fixed-duration venetoclax plus obinutuzumab in patients with CLL and comorbidities
Dr. Flinn on Venetoclax and Obinutuzumab in CLL
CLL14 trial: do certain patients benefit more from venetoclax plus obinutuzumab in CLL?
Achieving undetectable MRD with ibrutinib plus venetoclax for CLL
CLL14: Venetoclax plus obinutuzumab for CLL
MRD negativity and its role as a predictor for CLL patient responses
